PharmGen Science, Inc. (004720.KS)
KRW 4035.0
(0.62%)
KRW 4035.0
(0.62%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 13.37 Billion KRW | -86.41% |
| 2022 | 10.78 Billion KRW | 115.61% |
| 2021 | -1.79 Billion KRW | 165.52% |
| 2020 | 1.05 Billion KRW | 366.79% |
| 2019 | 3.51 Billion KRW | -37.82% |
| 2018 | 6.17 Billion KRW | -18.52% |
| 2017 | 6.84 Billion KRW | 26.42% |
| 2016 | 5.29 Billion KRW | 60.23% |
| 2015 | 5.34 Billion KRW | 228.19% |
| 2014 | -2.83 Billion KRW | -14.57% |
| 2013 | -2.42 Billion KRW | 24.38% |
| 2012 | -3.22 Billion KRW | 25.53% |
| 2011 | -2.73 Billion KRW | -664.02% |
| 2010 | 776.08 Million KRW | -83.54% |
| 2009 | 4.7 Billion KRW | -34.79% |
| 2008 | 5.38 Billion KRW | -4.16% |
| 2007 | 7.51 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 3.88 Billion KRW | -6.67% |
| 2024 Q1 | 4.16 Billion KRW | -19.43% |
| 2023 Q4 | 5.17 Billion KRW | -78.35% |
| 2023 Q1 | 21.82 Billion KRW | -75.43% |
| 2023 Q2 | 24.87 Billion KRW | 13.98% |
| 2023 Q3 | 23.88 Billion KRW | -3.97% |
| 2023 FY | - KRW | -86.41% |
| 2022 Q4 | 88.82 Billion KRW | 4151.9% |
| 2022 Q3 | 2.08 Billion KRW | 10.02% |
| 2022 Q2 | 1.89 Billion KRW | -52.86% |
| 2022 Q1 | 4.02 Billion KRW | -92.0% |
| 2022 FY | - KRW | 115.61% |
| 2021 Q3 | 1.6 Billion KRW | 135.94% |
| 2021 Q2 | -4.47 Billion KRW | -114.91% |
| 2021 Q1 | 30.03 Billion KRW | 161.31% |
| 2021 FY | - KRW | 165.52% |
| 2021 Q4 | 50.33 Billion KRW | 3027.97% |
| 2020 Q2 | 2.64 Billion KRW | 821.85% |
| 2020 FY | - KRW | 366.79% |
| 2020 Q4 | 11.49 Billion KRW | 252.38% |
| 2020 Q3 | 3.26 Billion KRW | 23.1% |
| 2020 Q1 | -367.08 Million KRW | -42.73% |
| 2019 Q4 | -257.19 Million KRW | -128.43% |
| 2019 Q2 | 1.66 Billion KRW | 17.53% |
| 2019 FY | - KRW | -37.82% |
| 2019 Q1 | 1.41 Billion KRW | 20.08% |
| 2019 Q3 | 904.59 Million KRW | -45.67% |
| 2018 Q4 | 1.17 Billion KRW | 175.67% |
| 2018 FY | - KRW | -18.52% |
| 2018 Q2 | 2.42 Billion KRW | 47.65% |
| 2018 Q3 | 427.97 Million KRW | -82.38% |
| 2018 Q1 | 1.64 Billion KRW | -4.14% |
| 2017 Q2 | 1.86 Billion KRW | 43.29% |
| 2017 FY | - KRW | 26.42% |
| 2017 Q4 | 1.71 Billion KRW | -26.91% |
| 2017 Q3 | 2.34 Billion KRW | 25.65% |
| 2017 Q1 | 1.3 Billion KRW | -43.84% |
| 2016 Q1 | 1.79 Billion KRW | 567.53% |
| 2016 Q3 | 904.91 Million KRW | 31.33% |
| 2016 Q4 | 2.32 Billion KRW | 156.67% |
| 2016 Q2 | 689.02 Million KRW | -61.52% |
| 2016 FY | - KRW | 60.23% |
| 2015 Q4 | 268.22 Million KRW | -63.58% |
| 2015 FY | - KRW | 228.19% |
| 2015 Q3 | 736.39 Million KRW | -65.97% |
| 2015 Q2 | 2.16 Billion KRW | 14.14% |
| 2015 Q1 | 1.89 Billion KRW | 199.77% |
| 2014 Q3 | -739.23 Million KRW | -95.18% |
| 2014 Q2 | -378.73 Million KRW | -57.35% |
| 2014 FY | - KRW | -14.57% |
| 2014 Q1 | -240.69 Million KRW | 83.75% |
| 2014 Q4 | -1.9 Billion KRW | -157.07% |
| 2013 Q3 | -971.02 Million KRW | -662.35% |
| 2013 Q4 | -1.48 Billion KRW | -52.57% |
| 2013 FY | - KRW | 24.38% |
| 2013 Q1 | -129.37 Million KRW | 97.35% |
| 2013 Q2 | 172.67 Million KRW | 233.47% |
| 2012 Q4 | -4.88 Billion KRW | -61895.22% |
| 2012 FY | - KRW | 25.53% |
| 2012 Q2 | -400.38 Million KRW | -128.65% |
| 2012 Q3 | -7.88 Million KRW | 98.03% |
| 2012 Q1 | 1.39 Billion KRW | 174.98% |
| 2011 Q1 | 1.76 Billion KRW | 156.69% |
| 2011 Q4 | -1.86 Billion KRW | -210.4% |
| 2011 FY | - KRW | -664.02% |
| 2011 Q2 | -6.29 Billion KRW | -457.07% |
| 2011 Q3 | 1.68 Billion KRW | 126.81% |
| 2010 Q3 | 1.11 Billion KRW | -25.21% |
| 2010 Q2 | 1.49 Billion KRW | 18.18% |
| 2010 Q1 | 1.26 Billion KRW | 352.71% |
| 2010 FY | - KRW | -83.54% |
| 2010 Q4 | -3.1 Billion KRW | -378.09% |
| 2009 Q2 | 977.52 Million KRW | -35.76% |
| 2009 Q4 | -500.68 Million KRW | -118.72% |
| 2009 Q3 | 2.67 Billion KRW | 173.66% |
| 2009 Q1 | 1.52 Billion KRW | 293.48% |
| 2009 FY | - KRW | -34.79% |
| 2008 Q1 | 4.11 Billion KRW | 180.99% |
| 2008 Q3 | 2.72 Billion KRW | 144.49% |
| 2008 Q4 | -786.52 Million KRW | -128.89% |
| 2008 FY | - KRW | -4.16% |
| 2008 Q2 | 1.11 Billion KRW | -72.96% |
| 2007 Q4 | 1.46 Billion KRW | 912.17% |
| 2007 Q2 | 2.08 Billion KRW | -48.06% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q3 | 144.82 Million KRW | -93.07% |
| 2007 Q1 | 4.02 Billion KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Daewoong Co., Ltd. | 248.36 Billion KRW | 94.615% |
| Wooridul Huebrain Limited | -20.87 Billion KRW | 164.063% |